Valproic acid inhibits proliferation and induces apoptosis in acute myeloid leukemia cells expressing P-gp and MRP1

Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells

Martin Göttlicher · The EMBO Journal · 2001 · 1.9K citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +10

Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously.

Wm. Kevin Kelly, Victoria M. Richon, Owen A. O’Connor et al. · PubMed · 2003 · 623 citations

Medicine, Oncology, Pharmacology +16

Cell biological mechanisms of multidrug resistance in tumors.

Sanford M. Simon, Melvin Schindler · Proceedings of the National Academy of Sciences · 1994 · 371 citations

Medicine, Oncology, Pharmacology +16

Molecular sequelae of histone deacetylase inhibition in human malignant B cells

Nicholas Mitsiades, Constantine S. Mitsiades, Paul G. Richardson et al. · Blood · 2003 · 293 citations

Life Sciences, Molecular Biology, Oncology +14

Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53

J A Vrana, Roy H. Decker, C R Johnson et al. · Oncogene · 1999 · 286 citations

Life Sciences, Cancer Biology, Oncology +14